Syntara Ltd
ASX:SNT

Watchlist Manager
Syntara Ltd Logo
Syntara Ltd
ASX:SNT
Watchlist
Price: 0.03 AUD -3.23% Market Closed
Market Cap: 49m AUD

Relative Value

The Relative Value of one SNT stock under the Base Case scenario is 0.02 AUD. Compared to the current market price of 0.03 AUD, Syntara Ltd is Overvalued by 22%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SNT Relative Value
Base Case
0.02 AUD
Overvaluation 22%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
22
vs Industry
10
Median 3Y
5.7
Median 5Y
2.9
Industry
2.6
vs History
vs Industry
Median 3Y
-3.1
Median 5Y
-5.3
Industry
21.6
Forward
-0.1
vs History
19
vs Industry
Median 3Y
-3.3
Median 5Y
-3.3
Industry
16.5
vs History
23
vs Industry
Median 3Y
-2.6
Median 5Y
-2.6
Industry
22.5
vs History
69
vs Industry
11
Median 3Y
3.2
Median 5Y
5.7
Industry
2.3
vs History
23
vs Industry
11
Median 3Y
4.1
Median 5Y
2.1
Industry
2.9
vs History
vs Industry
84
Median 3Y
0
Median 5Y
1
Industry
5.5
vs History
vs Industry
Median 3Y
-2.1
Median 5Y
-2.6
Industry
13
Forward
-1.3
vs History
vs Industry
Median 3Y
-2.1
Median 5Y
-2.6
Industry
16.6
Forward
-3
vs History
19
vs Industry
Median 3Y
-2
Median 5Y
-2.2
Industry
15.8
vs History
22
vs Industry
Median 3Y
-2
Median 5Y
-2.2
Industry
19.1
vs History
23
vs Industry
3
Median 3Y
3
Median 5Y
2.6
Industry
1.9

Multiples Across Competitors

SNT Competitors Multiples
Syntara Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Syntara Ltd
ASX:SNT
48.7m AUD 6.5 -6.2 -2.7 -2.7
US
Eli Lilly and Co
NYSE:LLY
997.2B USD 16.8 54.2 36.3 39
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
503.6B USD 5.5 20 16.4 21.3
CH
Roche Holding AG
SIX:ROG
251.4B CHF 4.1 26.7 11.4 13.3
UK
AstraZeneca PLC
LSE:AZN
211.3B GBP 4.9 30.2 108.7 159.1
CH
Novartis AG
SIX:NOVN
206.9B CHF 4.6 18.1 11.5 14.8
US
Merck & Co Inc
NYSE:MRK
244.4B USD 3.8 12.8 9.2 10.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.3 13.1 9.1 10.6
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
145.2B USD 2.3 14.8 7.5 10.3
P/E Multiple
Earnings Growth PEG
AU
Syntara Ltd
ASX:SNT
Average P/E: 23.7
Negative Multiple: -6.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.2
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.7
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30.2
38%
0.8
CH
Novartis AG
SIX:NOVN
18.1
17%
1.1
US
Merck & Co Inc
NYSE:MRK
12.8
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.1
4%
3.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.8
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Syntara Ltd
ASX:SNT
Average EV/EBITDA: 438.8
Negative Multiple: -2.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.3
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.4
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.4
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.7
10%
10.9
CH
Novartis AG
SIX:NOVN
11.5
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.2
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.1
2%
4.6
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
1%
7.5
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Syntara Ltd
ASX:SNT
Average EV/EBIT: 1 881.2
Negative Multiple: -2.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.3
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.3
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
159.1
23%
6.9
CH
Novartis AG
SIX:NOVN
14.8
12%
1.2
US
Merck & Co Inc
NYSE:MRK
10.9
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.6
1%
10.6
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
8%
1.3